Company profile
ALDEYRA THERAPEUTICS, INC.
NASDAQ:ALDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| METHOTREXATE | phase3 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (35)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07402876 | phase3 | recruiting | 2026-02-01 | 2026-12-01 | Aldeyra Therapeutics, Inc. | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma |
| NCT06685692 | phase2 | completed | 2024-11-04 | 2025-06-18 | Aldeyra Therapeutics, Inc. | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) |
| NCT05717920 | phase2 | completed | 2023-02-15 | 2023-11-21 | Aldeyra Therapeutics, Inc. | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) |
| NCT04971031 | phase2 | completed | 2021-06-15 | 2021-09-08 | Aldeyra Therapeutics, Inc. | A Clinical Trial to Assess Subjects With Dry Eye Disease. |
| NCT06389214 | phase3 | completed | 2024-04-09 | 2024-06-11 | Aldeyra Therapeutics, Inc. | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease |
FDA applications (0)
No records yet.